Inverted CCAAT box-binding protein of 90 kDa (ICBP90) is over-expressed in several types of cancer, including breast, prostate and lung cancers. In search for proteins that interact with the set and ring-associated (SRA) domain of ICBP90, we used the two-hybrid system and screened a placental cDNA library. Several clones coding for a new domain of DNMT1 were found. The interaction, between the ICBP90 SRA domain and the DNMT1 domain, has been confirmed with purified proteins by glutathione-Stransferase pull-down experiments. We checked whether ICBP90 and DNMT1 are present in the same macromolecular complexes in Jurkat cells and immortalized human vascular smooth muscle cells (HVTs-SM1). Coimmunoprecipitation experiments showed that ICBP90 and DNMT1 are present in the same molecular complex, which was further confirmed by co-localization experiments as assessed by immunocytochemistry. Downregulation of ICBP90 and DNMT1 decreased VEGF gene expression, a major pro-angiogenic factor, whereas those of p16 INK4A gene and RB1 gene were significantly enhanced. Together, these results indicate that DNMT1 and ICBP90 are involved in VEGF gene expression, possibly via an interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 and an upregulation of p16
Inverted CCAAT box-binding protein of 90 kDa (ICBP90) is over-expressed in several types of cancer, including breast, prostate and lung cancers. In search for proteins that interact with the set and ring-associated (SRA) domain of ICBP90, we used the two-hybrid system and screened a placental cDNA library. Several clones coding for a new domain of DNMT1 were found. The interaction, between the ICBP90 SRA domain and the DNMT1 domain, has been confirmed with purified proteins by glutathione-Stransferase pull-down experiments. We checked whether ICBP90 and DNMT1 are present in the same macromolecular complexes in Jurkat cells and immortalized human vascular smooth muscle cells (HVTs-SM1). Coimmunoprecipitation experiments showed that ICBP90 and DNMT1 are present in the same molecular complex, which was further confirmed by co-localization experiments as assessed by immunocytochemistry. Downregulation of ICBP90 and DNMT1 decreased VEGF gene expression, a major pro-angiogenic factor, whereas those of p16 INK4A gene and RB1 gene were significantly enhanced. Together, these results indicate that DNMT1 and ICBP90 are involved in VEGF gene expression, possibly via an interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 and an upregulation of p16 Introduction ICBP90 (inverted CCAAT box-binding protein of 90 kDa, gene symbol UHRF1) is overexpressed in several cancer cell lines and cancer tissues including breast cancers (Hopfner et al., 2000; Mousli et al., 2003; Unoki et al., 2004; Jenkins et al., 2005) , cervical lesions (Lorenzato et al., 2005) , rhabdomyosarcomas (Schaaf et al., 2005) , pancreatic adenocarcinomas (CrnogoracJurcevic et al., 2005) , prostate cancers (Jenkins et al., 2005) and gliomas (Oba-Shinjo et al., 2005) . There are several lines of evidence that ICBP90 plays a role in tumorogenesis by deregulating the expression of genes involved in cancerogenesis. Among these genes, we can find topoisomerase IIa (Hopfner et al., 2000 (Hopfner et al., , 2002 , RB1 (Jeanblanc et al., 2005) and putatively p16
INK4A
, p14 ARF and RARb (Unoki et al., 2004) . ICBP90 and its mouse orthologue Np95 are required for cell proliferation particularly for the G 1 /S transition (Bonapace et al., 2002; Arima et al., 2004; Jeanblanc et al., 2005; Jenkins et al., 2005) . Considering that ICBP90 interacts with the RB1 gene product (Jeanblanc et al., 2005) which cooperates with the heterochromatin protein 1 and the histone methylase SUV39H1 to repress the cyclin E promoter (Nielsen et al., 2001) , ICBP90 is likely to play a role in gene silencing. Consistently with this, it has been shown that Np95 is involved in the pericentromeric heterochromatin replication (Papait et al., 2007) , a region known to be silenced. Furthermore, ICBP90 appears to be involved in the regulation of epigenetic events occurring during embryonic development and also in cancerogenesis Macaluso et al., 2007) . Consequently, one proposed function of ICBP90 is that it permanently represses tumour suppressor gene expression leading to loss of control of G 1 /S transition and therefore contributes to the cancerogenesis phenomenon . In addition, ICBP90 may also transiently repress tumour suppressor gene expression under physiological conditions (noncancerous) during the G 1 /S transition, as shown during fibroblast cell proliferation (Jeanblanc et al., 2005) .
The identification of ICBP90 partners would permit a significant breakthrough in the knowledge about its contribution to the cancerogenesis process. There are several domains in ICBP90 (Figure 1 ) that can bind putative partners. Indeed, ICBP90 contains an ubiquitinlike domain (NIRF_N), a SRA (set and ring-associated domain, also known as G9a or YDG domain) and two zinc finger domains, a plant homeo domain (PHD) and a really interesting new gene (RING) domain, both of which are hallmarks of E3 ligases (Ingham et al., 2004; Ohta and Fukuda, 2004) . The RING finger of ICBP90 exhibits E3 ligase activity (Jenkins et al., 2005) as does that of the mouse ICBP90 orthologue, Np95 (Citterio et al., 2004) .
To elucidate the role of ICBP90, we hypothesized that one of the key roles must rely on the SRA domain since in vertebrates only the UHRF family members contain such a domain . The SRA domain is a 150-170 amino acid long domain characterized by the conservation of up to 13 evenly spaced glycine residues and a VRV(I/V)RG motif (Baumbusch et al., 2001) . In the ICBP90 amino acid sequence this motif is VRVVRN and corresponds to amino acids 533-538. This domain is also known as the YDG domain because it contains a conserved YDG motif. The SRA domain of ICBP90 shows affinity for methylated CpG and HDAC1 (Unoki et al., 2004) . It has been proposed that this domain directs a number of heterogeneous proteins to the chromatin (Citterio et al., 2004) .
In searching for proteins interacting with the SRA domain of ICBP90, we used the two-hybrid system and a bait domain encompassing the SRA domain from amino acids 356-635. Interestingly, among the preys we found several clones that have in common a sequence of 215 amino acids, which showed 100% homology with the amino acid sequence of human DNMT1 extending from amino acids 401-615. DNMT1, a 1616 amino acid long protein, is the most abundant DNA methyltransferase. In somatic cells, it has a preference for hemimethylated DNA and by this way is believed to be the main enzyme responsible for copying and maintaining methylation patterns from the parental to the daughter strand after DNA replication (Turek-Plewa and Jagodzinski, 2005) . We named the domain of DNMT1 interacting with ICBP90, the 'SRA-binding domain' (SRA-BD).
It has been shown that the tumour suppressor gene p53 negatively regulates ICBP90 and vascular endothelial growth factor (VEGF) expression (Mukhopadhyay et al., 1995; Arima et al., 2004) and that the p16 INK4A gene, whose promoter is targeted by DNMT1 and ICBP90 (Suzuki et al., 2004; Unoki et al., 2004) , is a negative regulator of the VEGF gene expression (Miki et al., 2001) . Consequently, one of the goals of the present study was also to check whether both DNMT1 and ICBP90 could be involved in VEGF gene expression.
Results

Identification of a novel domain in DNMT1 that interacts with ICBP90
In order to identify proteins that interact with ICBP90 in the yeast two-hybrid system, we screened a human placenta library using a fragment encompassing the SRA domain of ICBP90 (that is, amino acids 356-635; Figure 1 and 'Materials and methods'). We identified 154 clones by histidine nutritional selection and b-galactosidase (b-gal) activity. The inserts from the isolated clones were sequenced, leading to the identification of 11 overlapping clones that encode a region of a protein named DNMT1 for DNA methyltransferase 1. The overlapping sequences of the yeast two-hybrid DNMT1 preys encompass a peptide that extends between residues 401-615 of human DNMT1. DNMT1 contains several domains (Figure 1 ) among them the Replication Foci Targeting Sequence (RFTS) was the closest to the preys since it overlaps the 55 first amino acids of the overlapping peptides.
We have confirmed the interaction of the SRA domain of ICBP90 with DNMT1 by glutathione-S-transferase (GST) pull-down assays. For this, we have produced the 401-615 polypeptide of DNMT1 fused to GST (GST-SRA-BD, 48 kDa) and the polypeptide AA 400 to AA 660 of ICBP90 encompassing the SRA domain (SRA, 29 kDa). Figure 2 shows that the SRA domain was pulled down in the presence of GST-SRA-BD but not with GST alone. These results show that purified SRA Figure 1 Structural organization of inverted CCAAT box-binding protein of 90 kDa (ICBP90) and DNMT1. The lengths of the ubiquitin-like domain (NIRF_N), the plant homeo domain (PHD) finger domain (C4HC3-type), the set and ring-associated (SRA) and the really interesting new gene (RING) finger (C3HC4-type) of ICBP90 are delimited by numerals corresponding to the positions of the amino acids. The bait protein of ICBP90, used for the twohybrid system, extends from amino acid 356 to 635 and comprises the SRA domain. The domains of DNMT1 are delimited by numerals and correspond to the positions of the amino acids (GenBank accession number P26358). The yeast two-hybrid preys are represented by black bars beneath the schematic representation of DNMT1 and the attached numerals correspond to the shortest amino acid sequences found in all preys. DMAP-1, DNMT1-associated protein 1; RFTS, replication foci targeting sequence; BAH, bromo-associated homology; SRA-BD, SRA binding domain.
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M Achour et al interacts with GST-SRA-BD but not with GST alone and demonstrate that the interaction of the two proteins is specific. Altogether, these results suggest that DNMT1 is a likely candidate to fulfil the requirements of an ICBP90 partner. The following experiments were carried out to check whether ICBP90 and DNMT1 will cooperate in vivo in a same macro-molecular complex to regulate VEGF gene expression.
ICBP90 and DNMT1 co-immunoprecipitate
Further experiments were carried out on Jurkat cells, leukaemic T lymphocytes, and conditionally immortalized human vascular smooth muscle cells (HVTs-SM1) (Hsieh et al., 2000) to demonstrate that ICBP90 colocalises with DNMT1. Jurkat cells were selected due to the fact that ICBP90 was first isolated via a Jurkat cDNA library screen in the one-hybrid system and that they have a high ICBP90 expression level (Hopfner et al., 2000; Jeanblanc et al., 2005) . The HVTs-SM1 cells were used as a vascular smooth muscle model since immortalized cells can be produced in large amounts and exhibit a uniform cell phenotype. Vascular smooth muscle cells are of particular interest as they are the most important source of VEGF from non-cancerous cells (Oak et al., 2005) . Furthermore, HVTs-SM1 have inactivated p53 (Hsieh et al., 2000) , thus allowing higher expression of ICBP90 since p53 is a negative regulator of ICBP90 (Arima et al., 2004) . Figure 3 shows the expression patterns of DNMT1, ICBP90 and HDAC1 in proliferating and confluent Jurkat cells before and after immunoprecipitation with anti-ICBP90 or anti-HDAC1 or anti-DNMT1 or with control antibodies (mouse IgG or anti-Ki67). Jurkat cells were treated with mimosine to block cells in late G 1 and prevent entry into S phase (Mousli et al., 2003; Jeanblanc et al., 2005) . DNMT1 shows higher expression in proliferating or mimosine-treated Jurkat cells than in confluent Jurkat cells (Figure 3a ). ICBP90 expression was quite similar in proliferating and in confluent Jurkat cells but was slightly more pronounced in mimosinetreated cells. HDAC1 was slightly increased in mimosine-treated Jurkat cells. Immunoprecipitation with the anti-ICBP90 mAb (Figure 3a ) or anti-HDAC1 or with anti-DNMT1 ( Figure 3b ) showed bands for DNMT1, ICBP90 and HDAC1 in all experimental conditions, with the highest amount found in mimosine-treated cells ( Figure 3a ). Negative controls were performed in the absence of precipitating antibody or with mouse IgG or with anti-Ki-67 that also detects a nuclear protein. In these conditions, no bands were observed for ICBP90, DNMT1 and HDAC1 (Figure 3a and b). These results suggest that, in Jurkat cells, ICBP90 is present in the same molecular complexes as DNMT1 and HDAC1. Immunoprecipitations were performed on whole proliferating Jurkat cell extracts without immunoprecipitating antibody (without Ab), or 5 mg of anti-HDAC1, or 10 mg of anti-DNMT1 or with 10 mg of anti-Ki-67 followed by immunoblotting. Immunoblot analysis was performed as described in 'Materials and methods'. Results are representative of three separate experiments.
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In HVTs-SM1, similar results were observed ( Figure 4 ). Indeed, DNMT1 and HDAC1 were present in immunoprecipitates obtained with anti-ICBP90 mAb, with higher amounts found in mimosine-treated cells (Figure 4a ). Conversely, ICBP90, DNMT1 and HDAC1 were found co-immunoprecipitated by anti-HDAC1 and anti-DNMT1 Abs ( Figure 4b ). As for the Jurkat cells, no bands were found for all negative controls. Considering the mimosine blocks cells in late G 1 by enhancing levels of p27 (Kip1); (Wang et al., 2000) , our results prove that DNMT1 and ICBP90 are already partners before entering into the S phase and suggest that their interaction is a prerequisite for such entry.
The presence of HDAC1 and ICBP90 and of ICBP90 and DNMT1 in the same macro-molecular complexes was confirmed in non-transformed primary human vascular smooth muscle cells (VSMCs) and human lung fibroblasts. Indeed, when using the anti-ICBP90 mAb as the precipitating antibody, DNMT1 and HDAC1 were found to be co-immunoprecipitated in proliferating VSMCs but not in confluent cells as a consequence of the lack of ICBP90 expression at confluency (Supplementary Figure   S1B) . When using the anti-DNMT1 mAb, ICBP90 and HDAC1 were co-immunoprecipitated in proliferating VSMCs (Supplementary Figure S1C) . The anti-Ki-67 mAb did not co-immunoprecipitate ICBP90 or HDAC1 or DNMT1 in VSMCs (Supplementary Figure S1A) .
The presence of DNMT1 and ICBP90 in the same complex was further confirmed in normal human lung fibroblasts but only while proliferating (Supplementary Figure S2 ). ICBP90 and DNMT1 showed weak expression in fibroblasts at confluence, whereas they appeared in large amounts during proliferation. Using the anti-DNMT1 mAb as the precipitating Ab, ICBP90 was found in the pellets of proliferating fibroblasts (Supplementary Figure S2 ). Altogether, these results suggest that the interaction of these two proteins is a crucial event during cell proliferation.
Immunocytochemistry was carried out on Jurkat cells ( showed that ICBP90 and DNMT1 were in general colocalized in discrete regions in the nucleus, and that the interaction between ICBP90 and DNMT1 is a highly frequent event. The labelling with both antibodies was restricted to the nucleus as assessed by phase contrast analysis. As a positive control, we confirmed that ICBP90 and HDAC1 are also co-localized in Jurkat cells (data not shown). In HVTs-SM1 cells, ICBP90 ( Figure 6a ) and DNMT1 ( Figure 6b ) were also co-localized in the entire nucleoplasm (Figure 6c ). The labelling was restricted to the nucleus. The less labelled areas correspond to the nucleolus.
The ICBP90/DNMT1 complex is involved in the regulation of the VEGF gene expression in Jurkat cells and HVTs-SM1 To investigate the role of the ICBP90/DNMT1 interaction and in order to show whether the ICBP90/DNMT1 complex could be involved in transcriptional regulatory pathways of the VEGF gene, we studied the effect of acute knockdown of ICBP90 and DNMT1 by using RNA interference (RNAi) in Jurkat and HVTs-SM1 cells. Transfection of Jurkat cells with small interfering RNAs (siRNA) specific for ICBP90 (ICBP90-408 siRNA, ICBP90-990 siRNA or the combination of ICBP90-408 siRNA and ICBP90-990 siRNA), but not with scramble siRNA, resulted in a large reduction in levels of ICBP90 protein (Figure 7a ). The knockdown of ICBP90 was accompanied by a downregulation of VEGF and DNMT1 expression in association with an upregulation of pRB and p16 INK4A (Figure 7a ). We further examined whether the VEGF gene expression is also dependent upon the DNMT1 expression. Transfection of Jurkat cells with siRNA specific for DNMT1 (DNMT1-517 siRNA), but not with the scramble siRNA, resulted in an (Figure 7b ). The data show that the variation,that is increase or decrease of expression, are due to changes in the mRNA amounts of each gene which can result from effects on the transcription or on the mRNA stability.
In HVTs-SM1 cells, the use of the same siRNAs to knockdown ICBP90, also led to a strong VEGF expression inhibition but had no effect on either HDAC1 or DNMT1 expressions ( Figure 8a ). As in Jurkat cells, the ICBP90 knockdown was accompanied by an increase in pRB and p16
INK4A expressions. DNMT1-517 siRNA caused a dramatic decrease in VEGF and ICBP90 expressions accompanied by increases in pRB and p16
INK4A expressions (Figure 8a ). These results have also been confirmed by analysing the mRNA expression of ICBP90, DNMT1, VEGF, pRB and p16 INK4A (Figure 8b ) showing that the variations in proteins are a consequence of mRNA changes. Together, these results suggest that ICBP90 and DNMT1 are involved in the expression of the VEGF gene in Jurkat cells as well as in HVTs-SM1 cells.
Discussion
In order to find putative partners of ICBP90, we screened a placenta cDNA library using the double hybrid system to search for proteins able to interact with the SRA domain of ICBP90. Among the preys, we isolated several clones that all encompass a common polypeptide sequence extending from amino acid 401-615 of the human DNMT1. This sequence partially overlaps the RFTS domain (Leonhardt et al., 1992) that extends from amino acid 207 to 455 (Figure 1) . It nevertheless seems unlikely that the 55 overlapping amino acids are sufficient for interaction with the SRA domain of ICBP90, since all preys extended at least to amino acid 615 that were largely over the end of the RFTS of DNMT1. This 55 amino acid polypeptide may ) and anti-DNMT1 (2 mg ml
À1
) and revealed with secondary Abs coupled to Alexa488 (green) and Phycoerythrin (red), respectively. Images are representative of four separate experiments. Scale bar: 10 mm.
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however bind to the SRA domain but may not be sufficient to confer maximal affinity of the SRA-BD for the ICBP90 SRA domain. Consequently, we propose that DNMT1 contains a new domain, called SRA-BD, for set and ring-associated binding domain. In mouse, it has been very recently reported that it is the PHD of 
Np95 that is interacting with a DNMT1 domain located between AA 1081 and AA 1408 and another located between AA 1 and AA 446 (Bostick et al., 2007) . The interaction between the SRA domain of ICBP90 and the SRA-BD of DNMT1 has been demonstrated in our study by two different techniques, but we cannot exclude that other parts of the two proteins may also interact. Nevertheless, it appears that the interactions are different in mouse compared to human. The importance of the SRA domain for DNA methylation has already been reported, but so far only in plants. Indeed, in Arabidopsis thaliana, the SRA ICBP90 interacts with DNMT1 and regulates VEGF expression M Achour et al domain of histone methyltransferases is involved in directing DNA methylation to the target sequences (Naumann et al., 2005) . It was shown that such DNA methylation is a pre-requisite for consecutive SUVH2 (a histone methyltransferase)-dependent histones H3 and H4 methylation to establish heterochromatin formation (Naumann et al., 2005) . Consistently with this and our results, it has been shown very recently that the mouse SRA domain has a sevenfold higher affinity for hemimethylated DNA than for fully methylated DNA (Bostick et al., 2007) . Furthermore, we have proposed that ICBP90 helps to tether DNMT1 to chromatin (Macaluso et al., 2007) . The SRA domain of ICBP90 has been previously shown to interact with HDAC1 and histones (Citterio et al., 2004; Unoki et al., 2004) . In accordance with this, it has been observed that Np95 (the mouse orthologue of ICBP90) plays a crucial role during heterochromatin replication by involving deacetylation of histones (Papait et al., 2007) . HDAC1 is also known to associate with DNMT1 (Fuks et al., 2000; Robertson et al., 2000; Macaluso et al., 2003) . It is thus likely that the SRA domain of ICBP90 binds at the same time HDAC1 and DNMT1. Considering that Np95 has ubiquitinating activity towards histones H3, H2A and H2B (Citterio et al., 2004) , such interaction may link histone ubiquitination, histone deacetylation and DNA methylation. Therefore, we hypothesize that heterochromatin replication requires the ICBP90/DNMT1 couple and that this complex induces mono-ubiquitination, methylation and deacetylation of histones and DNA methylation. Expression of DNMT1 is required for entry into the S phase and/or during its progression (Milutinovic et al., 2003; Chen et al., 2006) . This is in accordance with the demonstration that the interaction of DNMT1 with ICBP90 precedes S phase entry (present study).
In the present study, we report that the presence of ICBP90 and DNMT1 are essential for VEGF expression in Jurkat cells and in HVTs-SM1. Consequently, our results suggest that VEGF gene expression may require cells to enter the S phase and that this leads to production of transcription factors that induce transcription of the VEGF gene. This is in accordance with the p53 dependence of VEGF gene expression and the role of p53 in regulation of S phase entry (Levine, 1997) . Indeed, it has been previously shown that wild-type p53 downregulates endogenous levels of VEGF mRNA, as well as VEGF promoter activity, in a dose-dependent manner, whereas mutant forms of p53 had no effect (Mukhopadhyay et al., 1995) . These data suggest that wildtype p53 may play a role in suppressing angiogenesis. Interestingly, the fact that p53 is a negative regulator of ICBP90 expression (Arima et al., 2004) and that the VEGF gene promoter lacks any p53 binding site (Salimath et al., 2000) suggest that the role of p53 in angiogenesis can be mediated via a downregulation of ICBP90, thereby hindering the formation of the ICBP90/DNMT1 complex and preventing entry into S phase.
We have previously shown that ICBP90 associates with pRB and is a downregulator of the RB1 gene (Jeanblanc et al., 2005) . We hypothesized that the widely demonstrated anti-angiogenic properties of pRB (Gabellini et al., 2006 ) is due to downregulation of the VEGF gene expression. When we used siRNAs to downregulate ICBP90 and DNMT1 expressions, we observed that pRB expression was increased in Jurkat cells and HVTs-SM1. Nevertheless, since HVTs-SM1 have inactivated pRB, due to the interaction with large T antigen (Caracciolo et al., 2006; Giacinti and Giordano, 2006) , a direct involvement of pRB in the mechanism of action of ICBP90 on VEGF gene expression seems unlikely. Interestingly, downregulation of ICBP90 (present results) and DNMT1 (Fournel et al., 1999 and present is a negative regulator of the VEGF gene expression (Miki et al., 2001) , we propose that the ICBP90/DNMT1 complex can control VEGF expression via a downregulation of the p16 INK4A gene. DNMT1 has a preference for hemimethylated CpG sites generated during DNA replication by direct binding to proliferating cell nuclear antigen (PCNA) and thus maintains DNA methylation patterns in the newly synthesized strand after DNA replication (Leonhardt et al., 1992; Chuang et al., 2000) . DNMT1 is also involved in DNA repair machinery at sites of DNA damages (Mortusewicz et al., 2005) . The recruitment of DNMT1 at such sites appears to be mediated by PCNA (Mortusewicz et al., 2005) . Interestingly, ICBP90 or Np95 and PCNA also appear to be partners (Uemura et al., 2000; Arima et al., 2004) . In the present study, we observed that the DNMT1 expression is dependent upon ICBP90 expression in Jurkat cells but not in HVTs-SM1. In contrast, ICBP90 expression is dependent upon DNMT1 in both cell lines. This result is in accordance with our previous study in which inhibition of DNMT1 with 5-azacytidine has been shown to inhibit ICBP90 expression (Jeanblanc et al., 2005) . The mechanism by which these two proteins mutually control their expression is not yet investigated. However, an inhibition of DNMT1 expression by pRB is not excluded since ICBP90 increases the expression of this latter and that DNMT1 can be downregulated through the formation of E2F-pRB complexes (Kimura et al., 2003; McCabe et al., 2005) . Such inhibitory effect could not occur in HTVs-SM1 cells probably because they have inactivated pRB. Whatever the case maybe, these results suggest that DNA methylation controls histone ubiquitination and conversely histone ubiquitination controls DNA methylation. Consistently with this, it has been shown that DNMT1 is required for maintaining the histone H3 modification patterns in terms of acetylation and methylation (Espada et al., 2004) . The ICBP90 mediated mono-ubiquitination of histones and DNMT1 induced DNA methylation, might occur, in cancerogenesis, in the vicinity of tumour suppressor genes such as RB1, p16
INK4A or p14 ARF according to the cell type, considering that ICBP90 binds to methylated promoters of these genes (Unoki et al., 2004; Jeanblanc et al., 2005) . Interestingly, ICBP90 and DNMT1 are found overexpressed in several types of cancer (see Introduction; Peng et al., 2006; Vallbohmer et al., 2006) . We suggest that abnormal expression of the ICBP90/DNMT1 complex acts to downregulate tumour suppressor genes, which may be a key event in carcinogenesis.
In conclusion, the present study shows that the SRA domain of ICBP90 interacts with a novel domain of DNMT1 called the SRA-BD. This interaction occurs before the cells enter the S phase and is a pre-requisite for VEGF gene expression via a plausible downregulation of the p16 INK4A gene.
Materials and methods
Yeast two-hybrid screening Bait was PCR amplified (Pfu, Stratagene, Amsterdam, The Netherlands) and cloned into the pB27 plasmid derived from the original pBMT116 (Vojtek and Hollenberg, 1995) . The ICBP90 SRA domain encoded by the bait plasmid comprises residues 356 to 635 from human ICBP90. Random-primed cDNA library from human placenta poly (A) þ RNA was constructed into the pP6 plasmid derived from the original pGADGH (Bartel et al., 1993) . The library was transformed into the Y187 yeast strain and 10 million independent yeast colonies were collected, pooled and stored at À80 1C. The mating protocol has been described elsewhere (Rain et al., 2001) . The selectivity of the HIS3 reporter gene was modulated with 0.5 mM 3-aminotriazole. For the ICBP90 screen 72 million interactions (diploid yeast) were tested and 154 clones were picked. The prey fragments of the positive clones were amplified by PCR and sequenced at their 5 0 and 3 0 junctions on the PE3700 sequencer. The resulting sequences were used to identify the corresponding gene in the GeneBank database by using a fully automated procedure.
Chemicals and antibodies
The mouse monoclonal antibody (clone 1RC1C-10) raised against ICBP90 was engineered as described elsewhere (Hopfner et al., 2000) . Horseradish peroxydase-conjugated anti-mouse antibodies (for mAbs) were from Jackson Immunoresearch (West Grove, PA, USA). Horseradish peroxydase-conjugated anti-rabbit antibodies (for polyclonal antibodies) were from Cell Signaling (Danvers, MA, USA). Tween 20 and the protease inhibitor cocktail were purchased from Roche Diagnostics (Mannheim, Germany). The anti-Ki-67 (clone Mib-1) antibody was obtained from Dako SA (Trappes, France). L-mimosine and the mouse anti-b-tubulin Ab were obtained from SigmaAldrich (St Louis, MO, USA). The mouse anti-pRB mAb (clone MAB3186) was from Chemicon International (Temecula, CA, USA). The mouse anti-DNMT1 monoclonal antibody (clone 60B1220.1) was purchased from Stressgen (Victoria, BC, Canada) whereas the anti-DNMT1 polyclonal antibody was engineered by Proteogenix (Oberhausbergen, France). The rabbit polyclonal anti-p16
INK4A was from DeltaBiolabs (Gilroy, CA, USA). The mouse IgG used as a control in the immunoprecipitation experiments was obtained from Active Motif (Rixensart, Belgium). The rabbit anti-HDAC1 polyclonal antibody was from USBiological (Massachusetts, MA, USA). The rabbit anti-VEGF polyclonal antibody was from Tebu-Bio (Le Perray en Yvelines, France).
Pull-down assays
The DNMT1 SRA-BD cDNA (AA 401 to AA 615) was synthesized by PCR amplification using primers flanked with EcoRI and XhoI restriction sites with the following sequences; sense, 5 0 -ACGTGAATTCGCGCTTCCCCAGCACAAA-3 0 ; antisense 5
0 -GTGACTCGAGTTAGGGTCCCCTGTCCTT CT-3 0 : A cDNA library of the Jurkat cell line has been used as the template (Hopfner et al., 2000) . The cDNA was cloned into the pGEX-6P-1 vector (GE Healthcare, Munich, Germany) in order to obtain a GST-SRA-BD fusion protein. The GST-SRA-BD was over-expressed in Escherichia coli (E. coli) (BL21) and purification of the fusion protein was carried out by using glutathione-Sepharose beads (GE Healthcare). The cDNA of the SRA domain of ICBP90 (AA 400 to AA 660) was amplified by PCR, using the pSG5/ICBP90 plasmid as the template (Hopfner et al., 2000) . The primers were flanked with HindIII and EcoRI restrictions sites and have the following sequences: sense 5 0 -GGTAAAGCTTATGGCCTGTGTGGG CCGCA-3 0 ; antisense 5 0 -CGTGAATTCTCACCCGGCCCT GCTCGG-3 0 . The cDNA was cloned into the pT7MAT vector (Sigma). The his-tag protein was overexpressed in E. coli (BL21) and purified on Ni þ columns according the manufacturer's instructions (Sigma). GST pull-down assays were performed as described elsewhere (Jeanblanc et al., 2005) . Proteins were separated on 15% acrylamide sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and subsequently stained with Bio-Safe Coomassie (Bio-Rad, Hercules, CA, USA).
Cell cultures and cell synchronisation
The human T lymphocyte cell line Jurkat was obtained from the America Type Culture Collection (Mannassa, VA, USA) and was grown in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 100 U ml À1 penicillin and 50 mg ml À1 streptomycin. Immortalized human vascular smooth muscle cells (HVTs-SM1) were generated as described elsewhere (Hsieh et al., 2000) and subcultured in DMEM containing 15% FCS. The aortic human VSMCs were obtained from BioWhittaker (Cambrex, NY, USA) and were cultured in MCDB131 (Gibco, Carlsbad, NY, USA) containing 10% FCS, 0.5 ng ml À1 EGF, 2 ng ml À1 bFGF (Peprotech, Cell Concepts, Umkirch, Germany) and 5 mg ml À1 Insulin (Euromedex, Mundolsheim, France). Human lung fibroblasts in primary culture were prepared and cultured as described elsewhere (Hopfner et al., 2000) . To synchronize Jurkat and HVTs-SM1, cells were treated with L-mimosine (100 mg ml À1 ) for 20 h to arrest cells in the G 1 phase (Cheng and Kuchta, 1993) . All cultures and treatments were carried out at 37 1C.
Immunocytochemistry
Immunofluorescence staining of Jurkat cells and HVTs-SM1 was carried out as described elsewhere (Hopfner et al., 2000) . Briefly, cells were seeded at 20 000 cells per cm 2 and cultured on sterile glass slide with cover for 24 h. Fixed cells were first incubated with either 2 mg ml À1 of the mouse anti-ICBP90, 2 mg ml À1 of a polyclonal anti-DNMT1 or 2 mg ml À1 of the polyclonal anti-HDAC1 in phosphate-buffered solution, supplemented with 20% FCS overnight at 4 1C. Then, cells were washed and incubated with 4 mg ml À1 of a secondary antibody conjugated with Alexa488 (Goat anti-mouse, Invitrogen, Eugene, OR, USA) and 2 mg ml À1 of a biotinylated anti-rabbit Ab for 2 h. Polyclonal anti-DNMT1 Ab was revealed by sequentially using 2 mg ml À1 of R-Phycoerythrin conjugated Streptavidin (EXBIO, Prague, Czech Republic). After three washes with phosphate-buffered solution, the coverslips were mounted on slides with Vectashield (Vector laboratories, Burlingame, CA, USA) and observed with confocal laser scanning microscopy (Bio-Rad 1024, Kr-Ar laser 488 nm; Nikon Eclipse TE300, Â 40 oil-immersion CFI Plan-Fluor na 1.3 objective). Alexa488 and R-Phycoerythrin were excited at 488 and fluorescence was collected at 522 (green) and 585 nm ICBP90 interacts with DNMT1 and regulates VEGF expression M Achour et al (red). For fluorescence intensities and co-localization analysis, images were treated with Image J software.
Co-immunoprecipitation assays
For co-immunoprecipitation of DNMT1 and ICBP90, 1000 mg of Jurkat, HVTs-SM1, human vascular smooth muscle cells and human lung fibroblasts whole cell extracts were incubated with protein G beads coupled to either anti-ICBP90, anti-DNMT1, anti-HDAC1, anti-Ki-67 or mouse IgG (negative control) in phosphate-buffered solution supplemented with protease inhibitors for 2 h at 4 1C (Jeanblanc et al., 2005) . Beads were washed five times in 1 ml of phosphate-buffered solution and bound proteins were removed from the beads and denatured by Laemmli solution and separated on acrylamide SDS-PAGE as described hereafter.
Western blot
Whole-cell extract preparations were described elsewhere (Hopfner et al., 2000) . Proteins from cell lysates or from coimmunoprecipitates were loaded for one-dimensional electrophoresis on SDS-PAGE; 6% for the detection of DNMT1 and pRB, 10% for ICBP90, HDAC1, VEGF, and b-tubulin and 15% for p16
INK4A
. Blots were probed with anti-ICBP90 mAb (0.2 mg ml À1 ), anti-DNMT1 (2 mg ml À1 ), anti-pRB (2 mg ml À1 ), anti-HDAC1 (0.25 mg ml À1 ), anti-VEGF (1:5000), anti-b-tubulin (1:25 000) or anti-p16 INK4A (1:250). Secondary peroxidaseconjugated antibodies were diluted to 1:10 000. Signals were detected by chemiluminescence using the ECL detection system (Amersham Biosciences Europe GmbH, Saclay, France).
Real-time RT-PCR analysis
Total RNA was isolated by a Rneasy Micro KIT (Qiagen; Courtaboeuf, France). Total RNA (1 mg) was reverse transcribed by a modified Moloney murine leukaemia virus-derived reverse transcriptase using the iScript cDNA synthesis kit according to the manufacture's instructions (Bio-Rad). Realtime PCR was performed using the protocol recommended for the iQ SYBR Green Supermix from Bio-Rad in a MyIQ thermocycler (Bio-Rad). The results were normalized to those . Amplicons were size controlled on agarose gel and purity was assessed by analysis of the melting curves at the end of the real-time PCR reaction.
siRNA transfection
The sequences of the siRNA were as follows: ICBP90, 5
0 -GGUC AAUGAGUACGUCGAUdTdT-3 0 (corresponding to nucleotides 408-426 relative to the start codon), 5
0 -GCUCAUGUGCG AUGAGUGCdTdT-3 0 (nucleotides 990-1008) and DNMT1, 5 0 -AACGGUGCUCAUGCUUACAACdTdT-3 0 (nucleotides 517-537). The sequences of the scramble siRNA for ICBP90 and DNMT1, designed by and obtained from Sigma-Aldrich, were GGACUCUCGGAUUGUAAGAdTdT and GAUGGUC UACCGCUACAAACUdTdT, respectively. Transfections were performed using Lipofectamine (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocols. All experiments described in this paper were carried out on cells 72 h after siRNA (100 pmol) transfections at 0, 24 and 48 h.
